Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase

S L Archer, J M Huang, V Hampl, D P Nelson, P J Shultz, E K Weir, S L Archer, J M Huang, V Hampl, D P Nelson, P J Shultz, E K Weir

Abstract

Nitric oxide (NO)-induced relaxation is associated with increased levels of cGMP in vascular smooth muscle cells. However, the mechanism by which cGMP causes relaxation is unknown. This study tested the hypothesis that activation of Ca-sensitive K (KCa) channels, mediated by a cGMP-dependent protein kinase, is responsible for the relaxation occurring in response to cGMP. In rat pulmonary artery rings, cGMP-dependent, but not cGMP-independent, relaxation was inhibited by tetraethylammonium, a classical K-channel blocker, and charybdotoxin, an inhibitor of KCa channels. Increasing extracellular K concentration also inhibited cGMP-dependent relaxation, without reducing vascular smooth muscle cGMP levels. In whole-cell patch-clamp experiments, NO and cGMP increased whole-cell K current by activating KCa channels. This effect was mimicked by intracellular administration of (Sp)-guanosine cyclic 3',5'-phosphorothioate, a preferential cGMP-dependent protein kinase activator. Okadaic acid, a phosphatase inhibitor, enhanced whole-cell K current, consistent with an important role for channel phosphorylation in the activation of NO-responsive KCa channels. Thus NO and cGMP relax vascular smooth muscle by a cGMP-dependent protein kinase-dependent activation of K channels. This suggests that the final common pathway shared by NO and the nitrovasodilators is cGMP-dependent K-channel activation.

References

    1. Pflugers Arch. 1981 Aug;391(2):85-100
    1. Life Sci. 1993;53(14):1129-35
    1. Nature. 1985 Jan 24-30;313(6000):316-8
    1. J Pharmacol Exp Ther. 1986 Jun;237(3):893-900
    1. Nature. 1987 Jun 11-17;327(6122):524-6
    1. Circ Res. 1988 May;62(5):961-4
    1. Am J Physiol. 1988 Jul;255(1 Pt 2):H207-12
    1. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9360-4
    1. J Biol Chem. 1989 Mar 5;264(7):4028-32
    1. Biochem Biophys Res Commun. 1989 Aug 15;162(3):971-6
    1. Biochem Biophys Res Commun. 1989 Nov 15;164(3):1198-205
    1. J Biol Chem. 1990 Mar 25;265(9):5267-72
    1. Nature. 1990 Jul 5;346(6279):69-71
    1. J Biol Chem. 1990 Sep 5;265(25):14964-70
    1. Am J Physiol. 1990 Sep;259(3 Pt 2):H668-73
    1. J Pharmacol Exp Ther. 1991 Jan;256(1):371-7
    1. Circ Res. 1991 Jun;68(6):1569-81
    1. Am J Physiol. 1991 Oct;261(4 Pt 2):F600-6
    1. Br J Pharmacol. 1992 Feb;105(2):429-35
    1. Am J Physiol. 1992 Apr;262(4 Pt 1):C882-90
    1. J Pharmacol Exp Ther. 1992 Oct;263(1):194-200
    1. J Cardiovasc Pharmacol. 1992;20 Suppl 12:S72-5
    1. FASEB J. 1993 Feb 1;7(2):328-38
    1. FASEB J. 1993 Feb 1;7(2):349-60
    1. Pflugers Arch. 1993 May;423(3-4):167-72
    1. Am J Physiol. 1993 Jul;265(1 Pt 1):C299-303
    1. Annu Rev Pharmacol Toxicol. 1984;24:175-97

Source: PubMed

3
Abonneren